Institutional
GILEAD SCIENCES, INC. (GILD)
CIK 0000882095
$2.12B
Reported AUM
6
Positions
Q1 2026
Period
2026-05-08
Filed
The Brief · GILEAD SCIENCES, INC. (GILD) · Q1 2026
AI · grounded in 13F
GILEAD SCIENCES, INC. (GILD) trimmed its position in Xilio Therapeutics Inc XLO, reducing its share count by 92.86%. The fund added no new positions during the period. Total assets under management stood at $2.12B across six positions.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | — | — | — | — | $771.7M | 36.44% | — | HELD |
| 2 | RCUS | Arcus Biosciences Inc | $28.25 | 6.81% | 203.49% | -4.70% | $678.8M | 32.05% | — | HELD |
| 3 | LKFT | Galapagos NV | $27.64 | -0.29% | -15.26% | -52.87% | $501.2M | 23.67% | — | HELD |
| 4 | ASMB | Assembly Biosciences Inc | $26.06 | 3.78% | 36.11% | -45.08% | $125.0M | 5.90% | — | HELD |
| 5 | KYTX | Kyverna Therapeutics Inc | $7.49 | 5.94% | 114.83% | -70.25% | $35.6M | 1.68% | — | HELD |
| 6 | XLO | Xilio Therapeutics Inc | $9.08 | -0.22% | 0.77% | -95.86% | $5.5M | 0.26% | — | HELD |
Source: SEC EDGAR · accession 0001123292-26-000642. 13F discloses long positions only — shorts, foreign equities, and options are excluded.